Bruno Bergmans
YOU?
Author Swipe
View article: Foslevodopa/Foscarbidopa in Younger Patients Earlier Within Advanced Parkinson’s Disease: Post Hoc Analysis of a Randomized Trial
Foslevodopa/Foscarbidopa in Younger Patients Earlier Within Advanced Parkinson’s Disease: Post Hoc Analysis of a Randomized Trial Open
ClinicalTrials.gov identifier, NCT04380142.
View article: 3482 Correlation between sleep and quality of life in people with parkinson’s disease treated with continuous subcutaneous infusion of foslevodopa/foscarbidopa
3482 Correlation between sleep and quality of life in people with parkinson’s disease treated with continuous subcutaneous infusion of foslevodopa/foscarbidopa Open
View article: Independent validation and outlier analysis of EuroPOND Alzheimer’s disease staging model using ADNI and real-world clinical data
Independent validation and outlier analysis of EuroPOND Alzheimer’s disease staging model using ADNI and real-world clinical data Open
View article: Rare Abca7 Mutations in Alzheimer's Disease and Cerebral Amyloid Angiopathy Pathology
Rare Abca7 Mutations in Alzheimer's Disease and Cerebral Amyloid Angiopathy Pathology Open
View article: Festination-like steps during forward and backward gait while playing tennis
Festination-like steps during forward and backward gait while playing tennis Open
Festination is an episodic gait disorder which is often a precursor of freezing of gait episodes in Parkinson's disease patients. We discuss what lessons can be learned from a patient who had to quit playing tennis as he repeatedly fell du…
View article: Brain age as a biomarker for pathological versus healthy ageing – a REMEMBER study
Brain age as a biomarker for pathological versus healthy ageing – a REMEMBER study Open
Objectives This study aimed to evaluate the potential clinical value of a new brain age prediction model as a single interpretable variable representing the condition of our brain. Among many clinical use cases, brain age could be a novel …
View article: Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa
Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa Open
Background Foslevodopa/foscarbidopa is a subcutaneous infusion of levodopa/carbidopa prodrugs. Objectives Assess correlations between sleep and efficacy from interim data of a phase 3 trial of foslevodopa/foscarbidopa (NCT03781167). Method…
View article: Corrigendum to “Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson’s disease” [Clin. Parkinsonism Related Dis. 9 (2023) 100223]
Corrigendum to “Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson’s disease” [Clin. Parkinsonism Related Dis. 9 (2023) 100223] Open
[This corrects the article DOI: 10.1016/j.prdoa.2023.100223.].
View article: Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study Open
View article: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study Open
View article: Exome Sequencing and Multigene Panel Testing in 1,411 Patients With Adult-Onset Neurologic Disorders
Exome Sequencing and Multigene Panel Testing in 1,411 Patients With Adult-Onset Neurologic Disorders Open
ES and multigene panel testing is a powerful and efficient tool to diagnose patients with unexplained, adult-onset neurologic disorders.
View article: Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson’s disease
Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson’s disease Open
View article: The Lived Experiences of People with Progressive Supranuclear Palsy and Their Caregivers
The Lived Experiences of People with Progressive Supranuclear Palsy and Their Caregivers Open
This work represents a major collaborative effort to understand the lived experience of PSP. The research illustrates that a coordinated effort from all stakeholders is required to address ongoing needs and challenges within PSP.
View article: Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson’s disease population: an open-label, levodopa add-on study
Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson’s disease population: an open-label, levodopa add-on study Open
Background Safinamide is a recent multimodal antiparkinsonian drug that inhibits monoamine oxidase B and modulates the glutamatergic system with positive effects on motor and nonmotor symptoms of Parkinson’s disease (PD). This post-hoc ana…
View article: Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus Open
View article: Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation
Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation Open
Animal models indicate that butyrate might reduce motor symptoms in Parkinson’s disease. Some dietary fibers are butyrogenic, but in Parkinson’s disease patients their butyrate stimulating capacity is unknown. Therefore, we investigated di…
View article: Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer’s Disease in a Clinical Setting: A REMEMBER Study
Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer’s Disease in a Clinical Setting: A REMEMBER Study Open
Background: Magnetic resonance imaging (MRI) has become important in the diagnostic work-up of neurodegenerative diseases. icobrain dm, a CE-labeled and FDA-cleared automated brain volumetry software, has shown potential in differentiating…
View article: A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial
A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial Open
View article: Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation.
Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation. Open
Datasets SCFA production in fecal samples of Parkinson's patients after in vitro fermentation with different fiber supplements 'databank commerciële substraten' and vegetable/quinoa fiber substrates 'databank reststromen'.Dataset re…
View article: Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation.
Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation. Open
Datasets SCFA production in fecal samples of Parkinson's patients after in vitro fermentation with different fiber supplements 'databank commerciële substraten' and vegetable/quinoa fiber substrates 'databank reststromen'.Dataset re…
View article: Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation.
Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation. Open
Datasets SCFA production in fecal samples of Parkinson's patients after in vitro fermentation with different fiber supplements 'databank commerciële substraten' and vegetable/quinoa fiber substrates 'databank reststromen'.Dataset re…
View article: Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation.
Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation. Open
Datasets SCFA production in fecal samples of Parkinson's patients after in vitro fermentation with different fiber supplements 'databank commerciële substraten' and vegetable/quinoa fiber substrates 'databank reststromen'.Dataset re…
View article: Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation.
Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation. Open
Datasets SCFA production in fecal samples of Parkinson's patients after in vitro fermentation with different fiber supplements 'databank commerciële substraten' and vegetable/quinoa fiber substrates 'databank reststromen'.Dataset re…
View article: Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation.
Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation. Open
Datasets SCFA production in fecal samples of Parkinson's patients after in vitro fermentation with different fiber supplements 'databank commerciële substraten' and vegetable/quinoa fiber substrates 'databank reststromen'.Dataset re…
View article: A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial1
A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial1 Open
Background: Safinamide modulates both dopaminergic and glutamatergic systems with positive effects on motor and non-motor symptoms of Parkinson’s disease (PD). The drug utilization study SYNAPSES was designed to investigate the use of safi…
View article: Contribution of homozygous and compound heterozygous missense mutations in VWA2 to Alzheimer’s disease
Contribution of homozygous and compound heterozygous missense mutations in VWA2 to Alzheimer’s disease Open
Alzheimer's disease is the most frequent diagnosis of neurodegenerative dementia with early (≤65 years) and late (>65 years) onset ages in familial and sporadic patients. Causal mutations in 3 autosomal dominant Alzheimer genes, i.e. amylo…
View article: Amyloid-β1–43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations
Amyloid-β1–43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations Open
Background Alzheimer’s disease (AD) mutations in amyloid precursor protein ( APP ) and presenilins ( PSENs ) could potentially lead to the production of longer amyloidogenic Aβ peptides. Amongst these, Aβ 1–43 is more prone to aggregation …
View article: Natural Course of <scp>Myoclonus‐Dystonia</scp> in Adulthood: Stable Motor Signs But Increased Psychiatry
Natural Course of <span>Myoclonus‐Dystonia</span> in Adulthood: Stable Motor Signs But Increased Psychiatry Open
Myoclonus‐dystonia (M‐D) is a rare hyperkinetic movement disorder characterized by upper body–predominant myoclonus and dystonia.1 A large proportion of cases are caused by autosomal‐dominant inherited mutations in the SGCE gene. In additi…
View article: Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation.
Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation. Open
Datasets SCFA production in fecal samples of Parkinson's patients after in vitro fermentation with different fiber supplements 'databank commerciële substraten' and vegetable/quinoa fiber substrates 'databank reststromen'.Dataset re…
View article: Myoclonus-dystonia: Distinctive motor and non-motor phenotype from other dystonia syndromes
Myoclonus-dystonia: Distinctive motor and non-motor phenotype from other dystonia syndromes Open